Off Patent
January 2026

Promacta Kit

eltrombopag olamine

Novartis Pharmaceuticals Corp

For suspension (oral) · NDA 207027

Last listed protection ended
January 13, 2026

The FDA listed 1 patent and 1 exclusivity for Promacta Kit, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 7,547,719
    Claims the drug substance, the drug product and a use (U-1306, U-1575, U-1736, U-2452)
  2. Ended
    Orphan drug exclusivity
    FDA code ODE*
  3. Ended
    Patent 7,547,719
    Pediatric extension: six more months